key: cord-0965027-wmqhxxwj
authors: Kanda, Tatsuo; Sasaki, Reina; Masuzaki, Ryota; Takahashi, Hiroshi; Mizutani, Taku; Matsumoto, Naoki; Nirei, Kazushige; Moriyama, Mitsuhiko
title: Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease
date: 2020-09-02
journal: Int J Mol Sci
DOI: 10.3390/ijms21176384
sha: dd589b76d5bb55f7536c4e328d529db0973ac4ea
doc_id: 965027
cord_uid: wmqhxxwj

Hepatitis A virus (HAV) infection occasionally leads to a critical condition in patients with or without chronic liver diseases. Acute-on-chronic liver disease includes acute-on-chronic liver failure (ACLF) and non-ACLF. In this review, we searched the literature concerning the association between HAV infection and chronic liver diseases in PubMed. Chronic liver diseases, such as metabolic associated fatty liver disease and alcoholic liver disease, coinfection with other viruses, and host genetic factors may be associated with severe hepatitis A. It is important to understand these conditions and mechanisms. There may be no etiological correlation between liver failure and HAV infection, but there is an association between the level of chronic liver damage and the severity of acute-on-chronic liver disease. While the application of an HAV vaccination is important for preventing HAV infection, the development of antivirals against HAV may be important for preventing the development of ACLF with HAV infection as an acute insult. The latter is all the more urgent given that the lives of patients with HAV infection and a chronic liver disease of another etiology may be at immediate risk.

Liver failure is a common disease with high mortality, and its incidence is increasing with the use of alcohol and the prevalence of obesity and diabetes [1] [2] [3] . It has also been reported that the prognosis of acute hepatitis or acute liver injury was affected by the preexistence of chronic liver diseases and cirrhosis [1, 2] , extrahepatic diseases, such as metabolic, malignant, and psychiatric diseases [4] , and host factors, such as older age and obesity [3, 5, 6] , although the etiology of acute insults is one of the most important risk factors for the development of severe liver diseases [1, 7] .

Hepatitis A virus (HAV) infection is still one of the major causes of acute hepatitis worldwide. HAV infection occasionally causes acute liver failure [4, 8] . It has been reported that a superinfection of HAV in patients with a chronic hepatitis C virus (HCV) infection is associated with fulminant hepatitis [9] , although much research denies this association [5, 10] . HAV infection rarely causes acute liver failure in patients without underlying chronic liver diseases [9] .

There are excellent, safe, and effective HAV vaccines to prevent HAV infection. However, HAV vaccination costs a lot. As no universal vaccination program against HAV infection exists in certain countries, such as Japan, it may be important to develop potential drugs against HAV infection [11] . Table 1 . Acute-on-chronic liver failure with hepatitis A virus (HAV) infection in patients with nonalcoholic steatohepatitis (NASH) or chronic alcoholic liver diseases (ALD). Fatty liver diseases associated with metabolic dysfunction are common and have a heterogeneous genetic predisposition, metabolic syndrome, and environmental factors [23] . Recently, experts suggested "MAFLD" should replace NAFLD/NASH [23] . The diagnosis of MAFLD is based on the detection of liver steatosis in the presence of overweight or obesity, diabetes mellitus, and/or clinical evidence of metabolic abnormalities, such as hypertension, dyslipidemia, and hyperglycemia.

A Japanese nationwide survey of ALF and late-onset hepatic failure (LOHF) caused by HAV infection suggested that diabetic mellitus was more common among deceased patients than among rescued patients (29% vs. 8%; p < 0.05), excluding patients with liver transplantations, and that diabetic mellitus was independently associated with the outcome [24] . Patients with diabetes are at risk of developing severe hepatitis [25] .

We observed that HAV HA11-1299 genotype IIIA strain replication is enhanced by the accumulation of lipids or high-concentration glucose in the human hepatoma cell line, Huh7 [26] [27] [28] . Hyperglycemia or the accumulation of lipids induces an endoplasmic reticulum (ER) stress response in human hepatocytes. HAV replicates in the ER of human hepatocytes and induces an ER stress response. The ER stress response is mediated by the sensor molecules, inositol-requiring enzyme 1α (IRE1α), PKR-like ER kinase (PERK), and activating transcription factor 6 (ATF6), which are usually associated with molecular chaperone glucose-regulated protein 78 (GRP78) [27] . GRP78 is a negative regulator of ER stress response. We also observed that the overexpression of GRP78 could inhibit HAV replication, while the knockdown or knockout of GRP78 enhanced HAV replication [26, 28] . In sum, GRP78 is an antiviral protein against HAV replication [28] .

There are several factors affecting the severity of HAV infection and the rates of fulminant hepatic failure [29] . These important factors include older age, concomitant virus infection, chronic liver disease, sexual orientation, intravenous drug use, and alcohol abuse [6, 29] . Feller et al. reported that 12 patients developed hepatic encephalopathy, ascites, or both, among 20 patients with alcoholic cirrhosis and a superimposed episode of acute viral hepatitis [30] . HAV infection was excluded in only three of these patients [30] .

Lefilliatre et al. reported that three patients with fulminant hepatitis A had preexisting liver diseases, and one of the three had biopsy-proven alcoholic cirrhosis [21] (Table 1) . Spada et al. reported that two individuals were HCV-coinfected alcohol abusers, had underlying liver cirrhosis, and died of acute liver failure due to HAV infection [22] (Table 1) .

While the direct effects of alcohol on HAV replication is unknown, excess alcohol intake (binge drinking) could induce hepatic fibrosis. As only alcohol intake is responsible for worsening ACLF with alcoholic chronic liver diseases and alcoholic cirrhosis [31] , HAV may have an additive responsibility for worsening ACLF with ALD.

In Japan, where no universal vaccination programs against HAV infection exist, 10-20% of those with HIV infection tested positive for immunoglobulin G (IgG) anti-hepatitis A (HA) antibodies [32] [33] [34] [35] . This prevalence is similar to that of IgG anti-HA in those without HIV infection [36, 37] , although a higher prevalence area can also be observed in Japan [38] . In general, individuals of high-risk groups, such as healthcare workers, sewage workers, and drug addicts, have~60% of IgG anti-HA worldwide [39, 40] . The seroprevalence of IgG anti-HA is relatively higher in people living with HIV worldwide [41] [42] [43] .

HIV infection has also been reported as a cause of liver damage in patients infected with HIV [40] . Thus, it is as important to consider patients with HIV infection as those with chronic liver disease. Not only chronic viral hepatitis B or C but also drug-induced liver injury induced by the antiretroviral drugs, NAFLD and ALD, has also been observed in people with HIV [40] .

HAV infection in patients with chronic liver diseases and coinfected with HIV are shown in Table 2 [21, 22, 44, 45] . Prolonged HAV infection was also reported in an HIV-seropositive patient [44] . It was reported that the recovery of immunity through recently developed anti-HIV therapies may lead to more severe hepatocellular damage in patients with HAV infection [45] .

HAV infects humans through fecal-oral routes, when HAV-contaminated water and food are consumed. Among men who have sex with men (MSM), HAV is sexually transmitted [46] , and HAV outbreaks have been observed [47] [48] [49] [50] [51] [52] [53] [54] [55] . It is noteworthy that acute hepatitis A among MSM is one of the male-dominant diseases, although, in general, no gender difference exists in patients with an HAV infection caused by HAV-contaminated water and food. While HAV may cause severe hepatitis in people living with HIV, two doses of an HAV vaccine are more effective for them to achieve a sustained HAV seroresponse than a single dose of an HAV vaccine [56] . 

Several cases of ACLF with HAV as an acute insult and chronic hepatitis or cirrhosis due to HBV, as well as cases with a superinfection of HAV in patients with HBV, have been reported (Table 3 ) [9, 21, [57] [58] [59] [60] [61] [62] . A superinfection of HBsAg carriers with HAV seems not to cause more severe conditions [57] . Patients with HBV plus HAV infection had a less advanced baseline liver disease and a better prognosis than those with HBV plus hepatitis E virus infection [60] . Vento et al. reported that, among 10 patients with an acquired HAV superinfection and chronic HBV infection, one (10%), who had cirrhosis, had marked cholestasis [9] . Pramoolsinsap et al. evaluated acute superinfection with HAV in 20 HBV asymptomatic carriers and fulminant hepatitis or submassive hepatitis in 11 (55%) of 20 HBsAg carriers [63] . A superinfection of HAV in patients with HBV occasionally leads to critical conditions in HBV carriers with or without cirrhosis, although patients with advanced fibrosis or cirrhosis are more susceptible to severe conditions [9, 21, [57] [58] [59] [60] [61] [62] [63] .

A total of 310,746 cases with acute hepatitis A were observed during the Shanghai hepatitis A epidemic [58] . A total of 47 fatal cases (0.015%) were reported. Fatality rates were 0.05% (15/27,346) and 0.009% (25/283,400) in patients with or without HBV infection, respectively. It is worth noting that there were 5.6-fold greater fatality rates in patients with HBV infection than in those without [58] . Cooksley et al. reported that patients infected with HBV who have raised ALT levels and high HBV levels have a higher risk of liver failure following HAV superinfection [58] . HAV vaccination seems to be effective in preventing liver failure associated with HAV in patients with or without HBV infection [64] [65] [66] [67] . However, HAV vaccination may not be necessary in the case of countries in which HAV is endemic, such as India [68, 69] .

It has been reported that the transient suppression of HBV replication and the disappearance of HBV DNA with the seroconversion of HBeAg were observed in several cases of double infections with HAV and HBV carries [57] . Beisel et al. also reported that an HBsAg carrier case with HAV superinfection presented the seroconversion of HBsAg, suggesting that unspecific immunological responses to HAV could lead to a functional cure of HBV [62] . It was reported that the sharp peak in interferon-gamma production induced by a superinfection of HAV may lead to the suppression of HBV replication in patients with chronic hepatitis B [70] . This peak in interferon-gamma production occurred just before the rise in serum transaminase activity, resulting in a decrease in HBV DNA and HBeAg.

Berthillon et al. infected the human hepatoma cell line, PLC/PRF/5 [71] , which integrates HBV DNA and produces HBsAg, with the HAV CF53 strain [72] . The inhibition of HBsAg production in PLC/PRF/5 cells infected with HAV was observed, compared with those without HAV infection, demonstrating that HAV interferes with the expression of HBsAg from hepatocytes harboring integrated HBV DNA sequences [71] . We also infected HepG2.2.15, which produces HBV virion or HepG2 cells, with the HAV HA11-1299 strain. We demonstrated that the HAV replication is similar between HepG2.2.15 and HepG2, 96 h after HAV infection. However, HBV replication is inhibited in HAV-infected HepG2.2.15, compared to HepG2.2.15 without HAV infection [73] .

We also observed that the replication of both HAV and HBV is suppressed in human hepatocyte PXB cells superinfected with HAV and HBV, compared to those mono-infected with HAV or HBV [73] . Thus, HAV infection seems to inhibit HBV replication. Further studies are required to support this point, although it indicates that the existence of cirrhosis or advanced liver fibrosis should cause severe hepatitis in the superinfection of HAV in patients with HBV.

In general, HCV is a rare cause of fulminant hepatitis or acute liver failure [74, 75] . We did not identify any cases of fulminant hepatitis with HCV RNA in 82 cases of fulminant hepatitis and late-onset hepatic failure from 1986 to 2001, which were examined at Chiba University School of Medicine, Japan [74] . There were several reports that HAV infection in patients with chronic hepatitis C is associated with increased mortality [9, 21, 22, 76] , although several contrary opinions exist [59, 77] ( Table 4 ). Table 4 . Acute-on-chronic liver failure (ACLF) and/or the superinfection of hepatitis virus (HAV) in patients with hepatitis C virus (HCV). Vento et al. reported that, among 17 patients with an acquired HAV superinfection with chronic hepatitis C, seven patients (41.2%) possessed fulminant hepatic failure, and six (85.7%) of those seven patients died [9] . It is interesting to note that antinuclear antibodies, anti-smooth-muscle antibodies, and/or anti-asialoglycoprotein receptor antibodies were detected in five of seven patients with fulminant hepatitis (71.4%) [9] . Moreover, six of these seven patients possessed chronic active hepatitis, and one patient recovered from fulminant hepatitis and was treated with methylprednisolone [9] . There are some reports indicating a higher fatality rate of HAV superinfection in patients with chronic HCV infection, not considering those with or without cirrhosis [21] . However, it is unclear whether the high fatality rates were due to severe underlying liver damage or not [21, 22] .

It was reported that the superinfection of HAV is associated with decreased HCV replication, which may lead to a clearance of HCV [77, 78] . Esser-Nobis et al. found that Huh7-Lunet cells supported HAV and HCV replication with similar efficacy and limited interference with each other [79] .

In fact, as several severe hepatitis A cases have been observed in patients with chronic HCV infection, clinicians should pay attention to HAV infection in HCV-infected individuals [80] . At present, although direct-acting antivirals against HCV can lead to a higher sustained virological response with less adverse events, no effective HCV vaccines are available. Thus, HAV vaccination should be considered for HCV-infected patients, especially those with cirrhosis or advanced fibrosis [81] [82] [83] [84] [85] [86] [87] [88] .

It was reported that a prospective study of 31 children in the age group of 1-16 years, who fulfilled the criteria for ACLF of the Asian Pacific Association for the Study of the Liver (APASL) 2008 consensus, found 13 ACLF cases of HAV as an acute insult and autoimmune hepatitis or Wilson disease as causes of chronic liver disease [15] . In children, acute-on-chronic liver diseases, HEV, and HAV are more frequently causes of acute insults and Wilson disease, while autoimmune liver disease and primary sclerosing cholangitis are more frequently causes of chronic liver disease [12] . It is possible that HAV infection, as an acute insult, could result in ACLF in patients with any chronic liver disease, especially cirrhosis. Careful attention should also be paid to HAV infection in adults and children who have certain chronic liver diseases.

Acute insults in ACLF are different, depending on the country in which they are found [2] . In Asian countries, European countries, and the United States, hepatic, hepatic, and extrahepatic or infection (extrahepatic) causes, respectively, are representative acute insults in the definition of the APASL, EASL, and NACSELD ACLF guidelines [2, [89] [90] [91] . Of course, not only a sanitary environment but also host genetic factors are different in these different regions. Among Mexican Americans, transforming growth factor beta 1 (TGFB1) rs1800469 (adjusted odds ratio (OR), 1.38; 95% confidence interval (CI), 1.14-1.68; P value adjusted for false discovery rate (FDR-P) = 0.017) and X-ray repair cross complementing 1 (XRCC1) rs1799782 (OR, 1.57; 95% CI, 1.27-1.94; FDR-P = 0.0007) were associated with an increased risk of HAV infection [92] . ATP-binding cassette subfamily B member 1 (ABCB1) rs1045642 (OR, 0.79; 95% CI, 0.71-0.89; FDR-P = 0.0007) was associated with a decreased risk [92] . Host genetic factors may also play an important role in determining the differential susceptibility to HAV infection [92] [93] [94] .

HAV vaccination may be important for patients with chronic liver diseases, especially those with cirrhosis [81] [82] [83] [84] [85] [86] [87] [88] . While a universal vaccination program against HAV seems to be the most effective solution for the prevention of HAV infection, it may be difficult to carry out this program worldwide due to the high costs of HAV vaccine production and its low effectiveness in certain countries in which the infection is endemic [88, 95] . HAV vaccination targeting certain populations may also be effective and important in this regard [96] . Antivirals against HAV infection may also be needed (Figure 1 ). The unknown causes for chronic injury constitute only 5-15% of cases of ACLF [2] . 

Japanese rice-koji miso extracts enhanced GRP78 expression and inhibited HAV HA11-1299 genotype IIIA strain replication in the human hepatocytes, Huh7 and PXB cells [97] . We investigated the effect of miso extracts on virus replication in HepG2.2.15 cells infected with the HAV HA11-1299 strain [73] . It is noteworthy that miso extracts have an inhibitory effect on HAV replication but no inhibitory effect on HBV replication. Japanese rice-koji miso extracts may have an inhibitory effect on HAV replication in patients superinfected with HAV and HBV.

The zinc homeostasis pathway was identified as a key pathway of the antiviral activity of Japanese rice-koji miso against HAV infection using transcriptome-sequencing analysis [98] . We also demonstrated that zinc sulfate has an inhibitory effect on HAV HA11-1299 replication in human hepatocytes with the enhancement of GRP78 expression [98] . As Japanese miso soup and zinc sulfate are traditional foods and drugs, respectively, they induce GRP78 expression and are useful and safe antiviral compounds against HAV, with fewer adverse events. Gut dysbiosis and increased permeability cause pathological bacterial translocation and endotoxemia, which play an important role in the development of ACLF [2] . HAV infects the liver by the gut-portal vein-liver axis through fecal-oral routes. The digestion and absorption of Japanese rice-koji miso extracts and zinc sulfate may be used through similar routes.

The inhibitory effects of interferon-alpha, interferon-gamma, interferon-lambda, ribavirin, amantadine, sirtinol, and AZD1480 as host-targeting drugs and HAV 3C cysteine protease inhibitors, as well as small interfering RNAs against HAV, as antivirals that directly act on HAV replication, have been reported [11, 46, 99] . Interferon has antiviral potential against HAV [100, 101] , but it is difficult to use interferon in patients with ACLF, as interferon generally has cytotoxicity. Peginterferon-lambda has fewer side effects than peginterferon-alpha and may be useful in some patients with HAV infection. Amantadine is a broad-spectrum antiviral and has an inhibitory effect on HAV replication through the targeting of HAV internal entry site (IRES) activity [100, 102, 103] . The sirtuin inhibitor, sirtinol, also inhibits HAV replication by inhibiting HAV IRES activity [104] . Further studies on the mechanism of the sirtuin inhibitor and JAK pathways in HAV replication are needed [104, 105] . In patients with chronic liver diseases or ACLF, these drugs should be improved, and more safe drugs are needed and should be explored. It has been reported that HCV receptor candidates, such as HAV cellular receptor 1 (HAVcr-1), integrin β1, and gangliosides, are the entry 

Japanese rice-koji miso extracts enhanced GRP78 expression and inhibited HAV HA11-1299 genotype IIIA strain replication in the human hepatocytes, Huh7 and PXB cells [97] . We investigated the effect of miso extracts on virus replication in HepG2.2.15 cells infected with the HAV HA11-1299 strain [73] . It is noteworthy that miso extracts have an inhibitory effect on HAV replication but no inhibitory effect on HBV replication. Japanese rice-koji miso extracts may have an inhibitory effect on HAV replication in patients superinfected with HAV and HBV.

The zinc homeostasis pathway was identified as a key pathway of the antiviral activity of Japanese rice-koji miso against HAV infection using transcriptome-sequencing analysis [98] . We also demonstrated that zinc sulfate has an inhibitory effect on HAV HA11-1299 replication in human hepatocytes with the enhancement of GRP78 expression [98] . As Japanese miso soup and zinc sulfate are traditional foods and drugs, respectively, they induce GRP78 expression and are useful and safe antiviral compounds against HAV, with fewer adverse events. Gut dysbiosis and increased permeability cause pathological bacterial translocation and endotoxemia, which play an important role in the development of ACLF [2] . HAV infects the liver by the gut-portal vein-liver axis through fecal-oral routes. The digestion and absorption of Japanese rice-koji miso extracts and zinc sulfate may be used through similar routes.

The inhibitory effects of interferon-alpha, interferon-gamma, interferon-lambda, ribavirin, amantadine, sirtinol, and AZD1480 as host-targeting drugs and HAV 3C cysteine protease inhibitors, as well as small interfering RNAs against HAV, as antivirals that directly act on HAV replication, have been reported [11, 46, 99] . Interferon has antiviral potential against HAV [100, 101] , but it is difficult to use interferon in patients with ACLF, as interferon generally has cytotoxicity. Peginterferon-lambda has fewer side effects than peginterferon-alpha and may be useful in some patients with HAV infection. Amantadine is a broad-spectrum antiviral and has an inhibitory effect on HAV replication through the targeting of HAV internal entry site (IRES) activity [100, 102, 103] . The sirtuin inhibitor, sirtinol, also inhibits HAV replication by inhibiting HAV IRES activity [104] . Further studies on the mechanism of the sirtuin inhibitor and JAK pathways in HAV replication are needed [104, 105] . In patients with chronic liver diseases or ACLF, these drugs should be improved, and more safe drugs are needed and should be explored. It has been reported that HCV receptor candidates, such as HAV cellular receptor 1 (HAVcr-1), integrin β1, and gangliosides, are the entry receptor candidates for HAV. Further studies in this vein are needed [106] [107] [108] . Gangliosides seem to function as endosome receptors for infection using both naked and quasi-enveloped HAV virions [108] . Blocking the cellular entry of HAV is also an attractive drug target for combating HAV infection.

Acute hepatitis A usually exhibits more severe inflammation, such as a higher fever and higher C-reactive protein levels, compared to acute hepatitis due to other hepatitis viruses [109] [110] [111] . Some cases of acute HAV infection present acute renal failure [112] [113] [114] . These results suggest that HAV infection activates human immune systems and induces cytokines [115] [116] [117] [118] [119] . Innate immunity also seems to be involved in the pathogenesis of hepatitis A [120, 121] . Hypergammaglobulinemia and a high occurrence of autoantibodies are observed in HAV infection [122, 123] . This may support the immunological basis of its pathogenesis. Moreover, the higher gammaglobulinemia in fulminant HAV suggests the existence of a more aggressive immunological reaction in severe hepatitis A [123] .

Severe systemic inflammation can affect the functions of somatic cells in tissue and modify the clinical manifestation of cirrhosis and ACLF [124, 125] . Patients with acute liver failure or ACLF are susceptible to infection, and early transplant-free survival is poor [126] [127] [128] [129] . In liver transplantation for patients with ACLF, the role of the timing, bridging, and management of liver transplantation is important [130, 131] .

It has recently been reported that HAV susceptibility parallels the high COVID-19 mortality [132] . The 2019 coronavirus disease (COVID-19) has been observed in Japan, where the HAV susceptibility of the general population is high [34, 35] . An HAV vaccination program is urgently required for individuals with or without HIV infection in this area. HAV infection is an imported infection, like novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [133] . In the era of COVID-19, attention should also be paid to dual infection with HAV and SARS-CoV-2.

An outbreak of HAV infection in MSM has been observed worldwide. An outbreak of acute HAV infection among HIV-coinfected MSM in Taiwan was observed from June 2015 to September 2017 [50, 134, 135] . Between July 2016 and February 2017, 48 male cases of HAV infection were found in the Netherlands [48] . A total of 17 of them were MSM. This strain is identical to a strain causing a large outbreak among MSM in Taiwan [48] . In the United States, HAV infections also increased among MSM from 2016 to 2018 [54, 136, 137] . Since 2017, HAV infection has increased among MSM in Japan [34, 37, 52] . RIVM-HAV16-090-like hepatitis A virus strains, which were >99.6% identical to the 66 reported strains isolated from Taiwan and European countries from 2015 to 2017, were also recovered from Japanese MSM [52] . A recent outbreak of HAV infection was also reported in various countries, such as Brazil, Spain, and Italy [53, [138] [139] [140] .

The molecular mechanism of the development of ACLF in patients with HAV infection is not fully understood. The possible mechanisms of the development of liver failure in the presence of coinfection with HCV and HAV are as follows. HAV is a virus that is generally sensitive to interferon [100] [101] [102] . In comparison with HCV, HAV induces a limited production of type I interferon when HAV infects chimpanzees [141] . Compared with HBV and HCV, HAV weakly induced the activation of NF-κB signaling pathways in human hepatocytes [142, 143] . While HAV VP3 activates cell growth signaling [143] , HAV VP1/2A reduces cell viabilities in HCV sub-genomic replicon cells [144] .

HAV is usually a non-cytopathic virus, and HAV inhibits double-stranded (dsRNA)-induced interferon-beta gene expression by influencing the interferon-beta enhanceosome, as well as dsRNA-induced apoptosis [145] . Compared with HBV and HCV, HAV could evade mitochondrial antiviral signaling protein (MAVS)-mediated type I interferon responses [146] . HAV 3ABC is capable of MAVS cleavage, like HCV NS3/4A, which cleaves MAVS and disrupts interferon signaling [147] . HAV 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein [148] . HCV induces interferon-beta signaling pathways in human hepatocytes [149] . Controlling the effects of interferon signaling may determine the prognosis of patients coinfected with HCV and HAV (Figure 2 ). HCV induces interferon-beta signaling pathways in human hepatocytes [149] . Controlling the effects of interferon signaling may determine the prognosis of patients coinfected with HCV and HAV (Figure 2 ). HBV is a stealth virus which efficiently infects humans without alerting the innate immune system, although HCV strongly induces but cunningly evades the innate immune response [150] . The high glucose and fat deposition of hepatocytes seem to induce a chaperon-mediated autophagy (CMA) [151] . CMA targets interferon-alpha receptor chain-1 for degradation, dampens hepatic innate immunity, and disrupts interferon signaling pathways [151] . CMA is also observed in patients with ALD or MAFLD [152, 153] . Altering interferon signaling may contribute to ALF-associated acute HAV infection. However, further studies are needed. Among HIV-positive patients with acute HAV infection, lower peaks in total bilirubin, AST, and ALT levels were observed in comparison with HIV- HBV is a stealth virus which efficiently infects humans without alerting the innate immune system, although HCV strongly induces but cunningly evades the innate immune response [150] . The high glucose and fat deposition of hepatocytes seem to induce a chaperon-mediated autophagy (CMA) [151] . CMA targets interferon-alpha receptor chain-1 for degradation, dampens hepatic innate immunity, and disrupts interferon signaling pathways [151] . CMA is also observed in patients with ALD or MAFLD [152, 153] . Altering interferon signaling may contribute to ALF-associated acute HAV infection. However, further studies are needed. Among HIV-positive patients with acute HAV infection, lower peaks in total bilirubin, AST, and ALT levels were observed in comparison with HIV-negative patients with acute HAV infection [154] , suggesting that weaker immune responses occur in HIV-positive patients. These immune responses could enhance HAV replication and modify the pathogenesis in HIV-positive patients with acute hepatitis A [155] .

We reviewed the literature concerning HAV infection in patients with chronic liver diseases. In patients with chronic liver diseases, HAV infection can occasionally lead to a critical condition, such as acute liver failure. There seems to be no etiological association between liver failure and HAV infection, but there is a significant correlation between the severity of liver disease and the degree to which the liver has already been damaged. While there are effective HAV vaccines currently in existence, antivirals against HAV should be further explored. The latter is urgent given that the lives of patients with HAV infection and a chronic liver disease of another etiology may be at immediate risk. 

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. 

Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis

Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update

Prevalence of obesity in patients with acute hepatitis; is severe obesity a risk factor for fulminant hepatitis in Japan? Hepatogastroenterology

Nationwide survey for acute liver failure and late-onset hepatic failure in Japan

Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?

Influence of load of hepatitis A virus on disease severity and its relationship with clinical manifestations in patients with hepatitis A

Intractable Hepato-Biliary Diseases Study Group of Japan. Infectious complications and timing for liver transplantation in autoimmune acute liver failure in Japan: A subanalysis based on nationwide surveys between 2010 and 2015

Hepatitis A outbreak associated with a revolving sushi bar in Chiba, Japan: Application of molecular epidemiology

Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C

Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus

Acute on chronic liver disease in children from the developing world: Recognition and prognosis

Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease

Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)

Predictors of outcome in acute-on-chronic liver failure in children

Hepatitis E and Acute-on-Chronic Liver Failure

A Case of Acute-on-Chronic Liver Failure (ACLF) Due to An Uncommon Acute and Chronic Event

NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study

Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: Two cases

Prolonged hepatitis caused by cytomegalovirus and non-alcoholic steatohepatitis in 16-year-old obese boy

Fulminant hepatitis A in patients with chronic liver disease

An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users

International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Deteriorated outcome of recent patients with acute liver failure and late-onset hepatic failure caused by infection with hepatitis A virus: A subanalysis of patients seen between 1998 and 2015 and enrolled in nationwide surveys in Japan

Patients with Diabetes Mellitus are Prone to Develop Severe Hepatitis and Liver Failure due to Hepatitis Virus Infection

Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression

Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pancreatic cancer cells exposed to endoplasmic reticulum stress

Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication

Fulminant hepatitis in patients with chronic liver disease

Acute viral hepatitis superimposed on alcoholic liver cirrhosis: Clinical and histopathologic features

Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF)

Seroepidemiology of hepatitis A, B, and D viruses and human T-lymphocyte tropic viruses in Japanese drug abusers

Infection of hepatitis A virus in Japanese haemophiliacs

Prevalence of Hepatitis a Immunity and Decision-tree Analysis Among Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus in Tokyo

Chinese residing in

Very low prevalence of anti-HAV in Japan: High potential for future outbreak

Comparison of the Clinical Features of Hepatitis A in People Living with HIV between Pandemics in 1999-2000 and 2017-2018 in the Metropolitan Area of Japan

Surveillance of Hepatitis Viruses in Several Small Islands of Japan by Ship: A Public Health Approach for Elimination of Hepatitis Viruses by 2030

Risk groups for hepatitis A virus infection

The burden of liver disease in human immunodeficiency virus-infected patients

Increasing hepatitis A IgG prevalence rate in men who have sex with men attending a sexual health clinic in London: Implications for immunization policy

Seroepidemiology of hepatitis A, hepatitis B and varicella virus in people living with HIV in Ireland

Missed Opportunities for Hepatitis A Vaccination Among MSM Initiating PrEP

Prolonged hepatitis A infection in an HIV-1 seropositive patient

Hepatitis A virus-associated fulminant hepatitis with human immunodeficiency virus coinfection

Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection

Outbreak of hepatitis A associated with men who have sex with men (MSM)

Hepatitis A outbreak among men who have sex with men (MSM) predominantly linked with the EuroPride, the Netherlands

Hepatitis A outbreak in men who have sex with men (MSM) in Brescia

Epidemiological characteristics and associated factors of acute hepatitis A outbreak among HIV-coinfected men who have sex with men in Taiwan

Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France

Full-genome characterization of the RIVM-HAV16-090-like hepatitis A virus strains recovered from Japanese men who have sex with men, with sporadic acute hepatitis A

The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period

Hepatitis A Virus Infections-United States

Acute Hepatitis A Outbreak Among Men Who Have Sex With Men in

Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough?

Double infections with hepatitis A and B viruses

What did we learn from the Shanghai hepatitis A epidemic?

Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection

Comparison of effects of hepatitis E or A viral superinfection in patients with chronic hepatitis B

Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses

Seroconversion of HBsAG coincides with hepatitis A super-infection: A case report

Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV

Epidemiology of hepatitis A in Asia and experience with the HAV vaccine in Hong Kong

Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection

A virological perspective on the need for vaccination

Hepatitis A in a human immunodeficiency virus-infected patient: Impending risk during the Tokyo Olympic Games in 2020

Hepatitis A vaccination in chronic liver disease: Is it really required in a tropical country like India?

Should one vaccinate patients with chronic liver disease for hepatitis A virus in India?

Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production

Inhibition of the expression of hepatitis A and B viruses (HAV and HBV) proteins by interferon in a human hepatocarcinoma cell line (PLC/PRF/5)

Analysis of HBV Genomes Integrated into the Genomes of Human Hepatoma PLC/PRF/5 Cells by HBV Sequence Capture-Based Next-Generation Sequencing

Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus

Acute hepatitis C virus infection, 1986-2001: A rare cause of fulminant hepatitis in Chiba

Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure

Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C

Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV

Clearance of HCV RNA following acute hepatitis A superinfection. Dig. Liver Dis

Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication

Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection

Risks associated with hepatitis A and hepatitis B in patients with hepatitis C

Hepatitis A virus infection in hepatitis C Brazilian patients

Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: Missed opportunities for vaccination

Does the race or gender of hepatitis C infected patients influence physicians' assessment of hepatitis A and hepatitis B serologic status?

Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus?

Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. Can

Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection

Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of quality measure implementation

Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis

NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis

Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in Mexican Americans

Association of Toll-like receptor 4 with hepatitis A virus infection in Assam

Genome-wide genetic investigation of serological measures of common infections

Viral excretion and antibody titers in children infected with hepatitis A virus from an orphanage in western India

The Impact of Vaccination Efforts on the Spatiotemporal Patterns of the Hepatitis A Outbreak in Michigan

Inhibitory effect of Japanese rice-koji miso extracts on hepatitis A virus replication in association with the elevation of glucose-regulated protein 78 expression

Antiviral activity of zinc sulfate against hepatitis A virus replication

Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors

Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha

Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation

Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells

Internal ribosomal entry-site activities of clinical isolate-derived hepatitis A virus and inhibitory effects of amantadine

The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity

The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells

Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus

Cellular entry and uncoating of naked and quasi-enveloped human hepatoviruses

Gangliosides are essential endosomal receptors for quasi-enveloped and naked hepatitis A virus

Hepatitis A virus genotype IA-infected patient with marked elevation of aspartate aminotransferase levels

A Cluster of Hepatitis A Infections Presumed to be Related to Asari Clams and Investigation of the Spread of Viral Contamination from Asari Clams

Characteristics of acute hepatitis A virus infection before and after 2001: A hospital-based study in Tokyo

Fatal acute hepatic failure in a family infected with the hepatitis A virus subgenotype IB: A case report

Role of high-volume plasma exchange in a case of a G6PD deficient patient presenting with HAV related acute liver failure and concomitant acute renal failure

A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure

CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner

Conjugated Bilirubin Upregulates TIM-3 Expression on CD4(+)CD25(+) T Cells: Anti-Inflammatory Implications for Hepatitis A Virus Infection

Tumor Necrosis Factor-producing T-regulatory Cells Are Associated With Severe Liver Injury in Patients With Acute Hepatitis A

Inherited IL-18BP deficiency in human fulminant viral hepatitis

Human genetic basis of fulminant viral hepatitis

Innate-like Cytotoxic Function of Bystander-Activated CD8(+) T Cells Is Associated with Liver Injury in Acute Hepatitis A

Innate Immunity to Enteric Hepatitis Viruses. Cold Spring Harb

Prolonged acute hepatitis A mimicking autoimmune hepatitis

Serological markers of autoimmunity in children with hepatitis A: Relation to acute and fulminant presentation

Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance

Effect of COVID-19 on patients with compensated chronic liver diseases

Opportunistic infection in the patients with acute liver failure: A report of three cases with one fatality

Opportunistic infection in patients with acute liver failure

Infectious complications, steroid use and timing for emergency liver transplantation in acute liver failure: Analysis in a Japanese center

Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis

Liver Transplantation for Acute-on-Chronic Liver Failure: Science or Fiction? Liver Transpl

Long-term outcomes of patients undergoing liver transplantation for acute-on-chronic liver failure

Imported Infections in Rural Mid-West United States-A Report from a Tertiary Care Center

Hepatitis A susceptibility parallels high COVID-19 mortality

Incidence of acute hepatitis A among HIV-positive patients during an outbreak among MSM in Taiwan: Impact of HAV vaccination

Outbreak of hepatitis A virus infection in Taiwan

CDC provides advice on recent hepatitis A outbreaks

Notes from the Field: Increase in Reported Hepatitis A Infections Among Men Who Have Sex with Men

Acute hepatitis due to hepatitis A virus during the 2017 epidemic expansion in Asturias

Origin of HAV strains responsible for 2016-2017 outbreak among MSM: Viral phylodynamics in Lazio region

Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA

Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer

Hepatitis A virus VP3 may activate serum response element associated transcription

Hepatitis A protein VP1-2A reduced cell viability in Huh-7 cells with hepatitis C virus subgenomic RNA replication

Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA

MAVS-dependent host species range and pathogenicity of human hepatitis A virus

Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor

Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein

Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes

Stealth and cunning: Hepatitis B and hepatitis C viruses

Chaperone-Mediated Autophagy in the Liver: Good or Bad? Cells

SNX10 mediates alcohol-induced liver injury and steatosis by regulating the activation of chaperone-mediated autophagy

New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery

Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection

Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review